Therapy Areas: Vaccines
GSK agrees acquisition of Affinivax
31 May 2022 -

British pharmaceutical company GSK plc (LSE:GSK) (NYSE:GSK) said on Tuesday that it has entered into a definitive agreement to acquire US-based Affinivax Inc, a clinical-stage biopharmaceutical company.

Affinivax is based in Cambridge, Boston, Massachusetts and is developing a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.

Pneumococcal disease - including pneumonia, meningitis, bloodstream infections, and milder diseases such as sinusitis and otitis media - remains a significant unmet medical need despite the availability of current pneumococcal vaccines, GSK said.

The number of pneumococcal serotypes in current vaccines is limited due to the degree of immunological interference observed when using existing conjugation technologies. Affinivax has developed the Multiple Antigen Presenting System (MAPS), a novel technology that supports higher valency than conventional conjugation technologies, enabling broader coverage against prevalent pneumococcal serotypes and potentially creating higher immunogenicity than current vaccines.

GSK will acquire the business for USD2.1bn upfront plus up to USD1.2bn in potential development milestones.